Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GridAI TechnologiesGRDX +1.08%26 5-Year RORE % is -96.45 as of Mar. 2026. GuruFocus rates GRDX with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,148 Biotechnology companies, GridAI Technologies ranks worse than 94.69% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
GridAI Technologies's 5-Year RORE % for the quarter that ended in Mar. 2026 was -96.45%.
The industry rank for GridAI Technologies's 5-Year RORE % or its related term are showing as below:
GRDX's 5-Year RORE % is ranked worse than 94.69% of 1148
companies
in the Biotechnology industry
Industry Median: -10.905
vs GRDX: -96.45
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
GridAI Technologies 5-Year RORE % Related Terms
GridAI Technologies 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for GridAI Technologies's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRDX vs CELU, NRSN, ZIVO: 5-Year RORE % Comparison
For the Biotechnology subindustry, GridAI Technologies's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GridAI Technologies 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GridAI Technologies's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where GridAI Technologies's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
GridAI Technologies (GRDX) has a 5-Year RORE % of -96.45 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on GridAI Technologies and its competitors. According to the industry distribution chart, GridAI Technologies ranks #1087 out of 1148 companies in the Biotechnology industry, placing it in the top 94.7%.
Is GridAI Technologies' 5-Year RORE % too high?
GridAI Technologies' current 5-Year RORE % is -96.45. Based on the distribution chart, GridAI Technologies ranks #1087 out of 1148 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GridAI Technologies has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does GridAI Technologies' 5-Year RORE % compare to CELU and NRSN?
According to the Biotechnology industry distribution chart, GridAI Technologies ranks #1087 out of 1148 companies for 5-Year RORE %. This places GridAI Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on GridAI Technologies and its competitors. GridAI Technologies's current 5-Year RORE % is -96.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GridAI Technologies stock overvalued right now?
GridAI Technologies (GRDX) has a current 5-Year RORE % of -96.45. The current 5-Year RORE % is -96.45. GridAI Technologies' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For GridAI Technologies (GRDX), the current 5-Year RORE % is -96.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
26GF Score
Get the complete analysis for GRDX
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRDX has been successfully added to your 
